Treatment Outcomes and Patient Satisfaction of Oral Lichen Planus Treatment

Launched by DAR AL ULOOM UNIVERSITY · May 16, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a treatment called honey in orabase for patients with a condition known as oral lichen planus (OLP), specifically the erosive and atrophic types. The goal is to see if this honey treatment can help relieve symptoms and improve the quality of life for patients compared to a standard medication called triamcinolone acetonide. Participants in the study will take either the honey treatment or a placebo (a non-active substance) every day for four months and will visit the clinic every two weeks for checkups. They will also keep a diary to track their symptoms and any additional treatments they may need.

To be eligible for this trial, participants should be between 35 and 60 years old and have a diagnosis of oral lichen planus with symptoms that can be treated. However, individuals with other oral health issues, certain medical conditions, allergies to honey or the standard treatment, or those who are pregnant or breastfeeding cannot participate. This study is currently active but not recruiting new participants. It offers a chance to potentially improve the management of OLP through a natural treatment approach while closely monitoring participants’ health throughout the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with a clinical diagnosis of oral lichen planus
• • Symptomatic OLP lesions (erosive/atrophic)
• • Participants are between 35 and 60 years old, who are able to adhere to the study protocol, and sign informed consent.
• Exclusion Criteria:
• • Patients with other oral mucosal disorders, or systemic conditions influencing OLP or wound healing, allergies or hypersensitivity to honey or triamcinolone
• • Patients who administer systemic corticosteroids or immunosuppressive agents.
• • Pregnancy or lactation
• • Inability to comprehend or adhere to study directives
• • Patients who are not able to sign an informed written consent